BioCardia reports Q3 2024 net loss $1.7M; CardiAMP data expected Q1 2025

BioCardia, Inc.

Net loss $1.7M for Q3 2024 vs $2.6M a year ago; R&D expenses fell to $931K from $1.9M.
CardiAMP Heart Failure Trial data lock expected Q4 2024, top line results Q1 2025.
FDA approved protocol amendment for confirmatory Heart Failure II Trial, expanding eligibility.
Japan's PMDA consultation scheduled for late November 2024 regarding US data-based approval.
Closed $7.2M upsized public offering in September 2024; FDA cleared steerable introducer sheath for commercial release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.